Filing Flows › BioScience Health Innovations (BHIC) › Q4 2025
BioScience Health Innovations (BHIC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
BioScience Health Innovations (BHIC) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), +158% from a year earlier and +39% from the quarter before. Operating margin was -10.0%, net loss $234K (14.9% of revenue).
BioScience Health Innovations, Q4 2025: revenue $1.6M (+158% year over year), operating margin -10.0%, net loss $234K, operating cash flow −$101K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +39% | +158% |
| Operating profit | −$157K | — | -1673% |
| Net earnings | −$234K | — | -2446% |
| Operating cash flow | −$101K | — | — |
What changed
Revenue was $1.6M in Q4 2025, up 158% year over year and up 39% from the previous quarter.
Gross margin was 36.4%, down 19.2 points from Q4 2024. Operating costs exceeded revenue by $157K, an operating margin of -10.0%. Operating expenses grew 121% against revenue growth of 158%. The quarter ended with a net loss of $234K, wider than the previous quarter's $9K loss.
Operating cash flow was −$101K. Working capital and other items added $133K.
Questions
What was BioScience Health Innovations' revenue in the fourth quarter 2025?
BioScience Health Innovations (BHIC) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), +158% from a year earlier and +39% from the quarter before.
Was BioScience Health Innovations profitable in the fourth quarter 2025?
Operating loss was $157K (-10.0% of revenue) and net loss $234K.